Inside Pfizer’s Oval Workplace drug pricing cope with Trump
Amid all of the hand-shaking and back-patting, it was maybe the phrase “friendship” that stood out essentially the most when the CEO of Pfizer joined President Trump to handle a drug pricing deal within the Oval Workplace.
“However most of all, Mr. President, I need to thanks on your management and on your friendship,” Albert Bourla, the drug big’s high government, stated from an Oval Workplace podium.
It was notable, specifically, as a result of the Trump administration’s posture towards the pharmaceutical business has largely been pushed by forces that aren’t sometimes marks of friendship: threats, and a tense negotiation.
The gathering on Tuesday, nonetheless, made clear that Bourla’s relationship with Trump, cast on the peak of the Covid pandemic when Pfizer was creating its vaccine, had allowed him to not solely ease investor considerations but additionally take a spin across the White Home that, for a second, shined a heat highlight on the pharmaceutical business.
This text is unique to STAT+ subscribers
Unlock this text — plus every day intelligence on Capitol Hill and the life sciences business — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
